Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Actuate Therapeutics IncNASDAQ: ACTU
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) remains negative
Q1 FY2026 property, plant & equipment (net) was $0, compared with $0 a year earlier.
Context
- Property, plant & equipment (net) amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Property, plant & equipment (net) increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Property, Plant & Equipment (Net) vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
- Property, plant & equipment (net) amounts to 0.0% of total assets for ACTU, versus a peer median of 11.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $98.3M USD | -9.1% | -2.1% | 26.4% | |
| Mar 2026 | $77.08M USD | -13.8% | -15.7% | 65.5% | |
| Mar 2026 | $22.62M USD | -35.9% | -22.8% | 9.4% | |
| Mar 2026 | $20.09M USD | -17.6% | -11.1% | 12.9% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $4.79M USD | -19.0% | -15.8% | 21.1% |
| Mar 2026 | CHF 4.71M CHF | +14.4% | -10.3% | 5.4% | |
| Mar 2026 | $3.39M USD | -91.5% | -60.7% | 0.7% | |
| Mar 2026 | $1.26M USD | -55.8% | -35.4% | 2.1% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding ACTU) | — | -18.3% | -15.8% | 11.1% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.